Outsourcing Pharma

SEPTEMBER 16, 2021

The US agency has given the go-ahead to Cour Pharmaceuticals to evaluate the safety and efficacy of CNP-201, a drug intended to treat peanut allergies.

Allergies 105

Allergies FDA Approval Drugs Regulation 105

pharmaphorum

FEBRUARY 19, 2024

Fast approaching the end of its patent life, Roche and Novartis’ Xolair is going out with a bang, picking up a new approval as the first and only drug therapy for people with food allergies in the US.

Allergies 126

Allergies Medicine Drugs 126

Fierce Pharma

FEBRUARY 16, 2024

People with food allergies finally have a drug that can help prevent severe outcomes—and it’s a drug that’s been on the market for two decades. People with food allergies finally have a drug that can help prevent severe outcomes—and it’s a drug that’s been on the market for two decades.

Allergies 119

Allergies FDA Approval Marketing Medicine 119

XTalks

FEBRUARY 26, 2024

The US Food and Drug Administration (FDA) has granted expanded approval to Genentech’s (part of Roche) Xolair (omalizumab) to help reduce allergic reactions to various foods after accidental exposure. The class of IgE-mediated food allergies includes 160 foods, with peanuts, milk, eggs, wheat, soy and tree nuts being the most common ones.

Allergies 100

Allergies FDA Approval Drugs Protein 100

Medical Xpress

NOVEMBER 28, 2022

Philip Li from the LKS Faculty of Medicine, The University of Hong Kong (HKUMed) has pioneered a new nurse-led penicillin allergy triage and testing strategy—the Hong Kong Drug Allergy Delabelling Initiative (HK-DADI), and demonstrated its effectiveness and safety compared to traditional allergy testing.

Allergies 98

Allergies Nurses Medicine Drugs 98

Fierce Pharma

SEPTEMBER 5, 2023

billion acquisition, Nestlé has finally found a new owner for its peanut allergy drug Palforzia. billion acquisition, Nestlé has finally found a new owner for its peanut allergy drug Palforzia. After lackluster sales dampened the initial enthusiasm that came with a $2.1

Allergies 78

Allergies Drugs Sales 78

pharmaphorum

DECEMBER 10, 2020

Moncef Slaoui, co-head of the US government’s Operation Warp Speed COVID-19 vaccine programme, made the comments after the UK drugs regulator advised those with severe allergies to avoid the vaccine. The post Coronavirus vaccine may have allergy warning in US, says expert appeared first on.

Allergies 103

Allergies Vaccination Vaccine Regulation 103

Outsourcing Pharma

AUGUST 29, 2024

The European Commission has approved ARS Pharmaceuticalsâ adrenaline nasal spray for the emergency treatment of severe allergies, EURneffy.

Allergies 92

Allergies Drug Delivery Drugs 92

XTalks

JANUARY 17, 2023

The US Food and Drug Administration (FDA) has added sesame to its list of major allergens, making it easier for people with sesame allergies to safely consume packaged food without fear of an allergic reaction. Related: Top 3 Allergy Friendly Food Brands. percent of children and adults in the US are allergic to sesame.

Allergies 98

Allergies Packaging Packaging Containment 98

Pharmaceutical Technology

AUGUST 5, 2022

No progress in drug discovery. “We On the other hand, I think the progress in drug discovery is nil,” comments Requena on the prion disease landscape. According to GlobalData’s Pharma Intelligence Center, there are only six drugs in active development for CJD, of which only one has been in clinical trials.

Drugs 299

Drugs Protein Vaccine Vaccination 299

Medical Xpress

APRIL 10, 2023

Spring allergies can be brutal, and many—but by no means all—sufferers reach for synthetic medications to combat their symptoms.

Allergies 75

Allergies Drugs 75

Bio Pharma Dive

AUGUST 27, 2024

New biotech Navigator is working on drugs for immune diseases. Meanwhile, UCB sold its neurology and allergy business in China, and J&J's Peter Fasolo will retire this year.

Allergies 148

Allergies Drugs 148

pharmaphorum

SEPTEMBER 4, 2023

Nestle sells underperforming peanut allergy drug Phil.Taylor Mon, 04/09/2023 - 10:49 Bookmark this

Allergies 59

Allergies Drugs 59

XTalks

MARCH 10, 2025

Genentechs asthma drug Xolair (omalizumab) now faces its first competitive biosimilar. Originally approved by the FDA over two decades ago for the treatment of moderate to severe persistent asthma, Xolair recently also gained approval for managing food allergies. billion by 2030.

Allergies 66

Allergies FDA Approval Antibody Trials 66

Drug Patent Watch

FEBRUARY 12, 2024

Annual Drug Patent Expirations for FLONASE+SENSIMIST+ALLERGY+RELIEF Flonase Sensimist Allergy Relief is a drug marketed by Glaxosmithkline Cons and is included in one NDA. It is available from two suppliers.

Allergies 59

Allergies Drugs Marketing 59

Drug Patent Watch

MAY 24, 2024

Annual Drug Patent Expirations for CHILDREN%27S+ADVIL+ALLERGY+SINUS For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com Source

Allergies 59

Allergies Drugs 59

Medical Xpress

FEBRUARY 16, 2023

What if an over-the-counter allergy medicine could help halt and even reverse multiple sclerosis? And if it did, could patients return to their full capacity? Those were some of the questions first posed in 2013 after a landmark discovery by UC San Francisco neuroscientist Jonah Chan, Ph.D., and physician-scientist Ari Green, MD.

Allergies 75

Allergies Scientist Medicine Drugs 75

BioPharma Reporter

MAY 20, 2022

The National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health, has awarded a total of $577m to establish nine Antiviral Drug Discovery (AViDD) Centers for Pathogens of Pandemic Concern.

Allergies 105

Allergies Drugs Development Drug Delivery 105

Pharmaceutical Technology

SEPTEMBER 16, 2022

These results are in line with those obtained from the placebo-controlled, double-blind ACTT-1 trial of the National Institute of Allergy and Infectious Diseases. In April, the US Food and Drug Administration approved the supplemental new drug application for Veklury as a treatment for paediatric Covid-19 patients aged more than 28 days.

Allergies 277

Allergies RNA Clinical Trials Clinical Trials 277

Drug Patent Watch

AUGUST 24, 2021

Annual Drug Patent Expirations for ASTEPRO+ALLERGY Astepro Allergy is a drug marketed by Bayer Hlthcare and is included in one NDA. The generic ingredient in ASTEPRO ALLERGY is azelastine hydrochloride.….

Allergies 52

Allergies Drugs Marketing 52

Drug Patent Watch

AUGUST 14, 2021

Annual Drug Patent Expirations for ASTEPRO+ALLERGY Astepro Allergy is a drug marketed by Bayer Hlthcare and is included in one NDA. The generic ingredient in ASTEPRO ALLERGY is azelastine hydrochloride.….

Allergies 52

Allergies Drugs Marketing 52

Drug Patent Watch

AUGUST 24, 2021

Annual Drug Patent Expirations for CHILDREN%27S+ASTEPRO+ALLERGY For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com.

Allergies 52

Allergies Drugs 52

Drug Patent Watch

AUGUST 14, 2021

Annual Drug Patent Expirations for CHILDREN%27S+ASTEPRO+ALLERGY For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com.

Allergies 52

Allergies Drugs 52

NY Times

DECEMBER 25, 2020

The patient, who has a severe shellfish allergy, recovered quickly with treatment. Until now, reports of severe reactions had been linked to the Pfizer vaccine.

Vaccine 145

Vaccine Vaccination Doctors Doctor 145

Pharmaceutical Technology

JUNE 28, 2022

grant from the National Institutes of Health (NIH) unit National Institute of Allergy and Infectious Diseases (NIAID) for developing a Covid-19 oral antiviral drug. The antiviral will be a low-dose drug which can be taken in the at-home setting. Those drugs that hinder only CLpro did not enhance the effects of remdesivir.

Development 147

Development Bioinformatics Drugs Allergies 147

Drug Patent Watch

AUGUST 2, 2021

Annual Drug Patent Expirations for FLONASE+SENSIMIST+ALLERGY+RELIEF Flonase Sensimist Allergy Relief is a drug marketed by Glaxosmithkline Cons and is included in one NDA. It is available from one supplier.

Allergies 52

Allergies Drugs Marketing 52

Drug Patent Watch

NOVEMBER 25, 2021

Annual Drug Patent Expirations for CHILDREN%27S+ALLEGRA+ALLERGY For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com.

Allergies 52

Allergies Drugs 52

pharmaphorum

OCTOBER 27, 2021

AIT involves the administration of controlled, low doses of allergens under the tongue or by subcutaneous injection in people with allergies, with the aim of desensitising the immune system to them and prevent allergic reactions. ” The post Allergy specialist Stallergenes taps Aptar for digital delivery appeared first on.

Allergies 64

Allergies Drug Delivery Development Marketing 64

Drug Patent Watch

DECEMBER 24, 2020

Annual Drug Patent Expirations for ALLEGRA-D+24+HOUR+ALLERGY+AND+CONGESTION Allegra-d 24 Hour Allergy And Congestion is a drug marketed by Sanofi Aventis Us and is included in one NDA. It is available from….

Allergies 52

Allergies Drugs Marketing 52

Medical Xpress

MAY 12, 2023

Food and Drug Administration voted Thursday to recommend approval of Neffy, the first epinephrine nasal spray for severe allergic reactions. Outside advisors for the U.S.

Allergies 104

Allergies Drugs 104

XTalks

SEPTEMBER 28, 2023

In most cases, commercials are regulated to ensure they provide accurate information, include the benefits and risks of the drugs and encourage viewers to talk to their healthcare providers about the medication. The report included a roundup of the top ten TV ad debuts this year, with pharma drugs clinching the top three spots.

Drugs 105

Drugs Allergies Branding FDA Approval 105

Scienmag

JUNE 27, 2022

million grant from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to develop a low-dose, oral COVID antiviral drug that can be administered at home. . — Rensselaer Polytechnic Institute researchers Gaetano Montelione and Christopher Cioffi will use a five-year, $3.5

Development 94

Development Allergies Research Drugs 94

XTalks

SEPTEMBER 27, 2024

Novartis and Genentech released a pair of new TV commercials for allergy and asthma drug Xolair (omalizumab) as part of a direct-to-consumer (DTC) nationwide campaign called “Accidents Happen.” The ad highlights that despite the care parents take in handling their children’s allergies, accidental exposure can happen.

Allergies 52

Allergies Marketing FDA Approval Drugs 52

NY Times

DECEMBER 18, 2020

Four people so far have had allergic reactions after getting the Pfizer-BioNTech vaccine. Experts say that shouldn’t deter most people from getting a jab.

Allergies 94

Allergies Vaccine Vaccination Clinical Trials 94

Camargo

NOVEMBER 24, 2020

Most are familiar with, know someone who uses, or take “pumps” themselves to prevent or relieve shortness of breath after an effort or during allergy season. Interest in the pulmonary route has also grown in recent years because delivering the drugs through the lungs allows direct systemic delivery and bypasses the first pass metabolism.

Drug Delivery 130

Drug Delivery Drugs Allergies Medicine 130

Druggist

APRIL 20, 2021

Today I will explore a different use of montelukast and answer the main question: can you use montelukast for allergies? Can you use montelukast for allergies? Classified as a leukotriene receptor antagonist (LTRA), montelukast has a distinct mechanism of action compared to other drugs, including those used to treat asthma.

Allergies 52

Allergies Licensing Licensing Drugs 52

XTalks

NOVEMBER 5, 2024

Its lead candidate, PL-14, targets nasal allergies and is scheduled for US Food and Drug Administration (FDA) submission via the 510(k) pathway, with preclinical trials expected to start in the second quarter of 2025 and pivotal trials by the end of 2025.

Drug Delivery 111

Drug Delivery Drugs Immune Response Allergies 111